Moderator:
David MacNaughtan, Head, Royalty Monetization Fund (DRI Capital)

Panelists:
Dr. Aled Edwards (Director & CEO, Structured Genomics Consortium)
Dr. Rafi Hofstein (CEO, MaRS Innovation)
Dr. Ken Sonnenfeld (Partner, King & Spalding LLC)

Dr. Raphael (Rafi) Hofstein, PhD, President and CEO, MaRS Innovation, spoke at the MaRS Future of Medicine Conference 2009. He was a panelist in the roundtable discussion, "Is Open Source a Feasible Model for Biotech?"

Dr. Hofstein joined MaRS Innovation from Israel, where he held the position of President and CEO of Hadasit Ltd., the technology transfer company of the Hadassah Medical Organization in Jerusalem. He has also served as Chair of Hadasit BioHolding Ltd., publically traded on the Tel Aviv Stock Exchange (TASE), since 2005. In these roles, he was responsible for the commercialization of intellectual property emerging from the Hadassah Medical Organization, clinical trials with industry partners, as well as the launch, development and strategic oversight of a series of medical devices, biomedicine and diagnostic equipment spin-off companies.

MaRS - Building Canada’s next generation of global technology companies. marsdd.com

Future of Medicine interview with Dr. Aled Edwards, PhD

Aled Edwards is Chief Executive of the SGC, an international public-private partnership created to increase substantially the number of protein structures of relevance to human health available in the public domain. He believes that the discovery of new medicines would be most efficiently accomplished by performing many aspects of drug discovery research, from discovery to clinical proof of concept, within pre-competitive research consortia, and by de-emphasizing the perceived value of patents. Edwards was scientific consultant for the Canadian dramatic TV series, ReGenesis, and has founded a number biotechnology companies.

MaRS - Building Canada’s next generation of global technology companies. marsdd.com

Future of Medicine interview with Greg Hines
President and CEO, ArcticDx Inc.

ArcticDx is a molecular diagnostic company commercializing two genetic tests; Colo-Risk™ for colorectal cancer and Macula-Risk™ for macular degeneration. Previously, Mr. Hines was President, CEO and Director of Tm Bioscience from 2000 until he sold the company to Luminex Corporation in 2007. At Tm Bioscience, he led the design, development and commercialization of a molecular diagnostic platform complete with a menu of molecular tests in the fields of human genetics, pharmacogenetics and infectious disease. Mr. Hines currently serves as Chairman of the Board of Directors for Genesis Genomics Inc. and as an Entrepreneur in Residence mentoring life science companies at the MaRS centre.

MaRS - Building Canada’s next generation of global technology companies. marsdd.com

Future of Medicine interview with Ken Sonnenfeld, PhD, partner, King and Spalding LLC

Dr. Sonnenfeld is a partner in the Intellectual Property group in the New York office. He has been practicing biotechnology and pharmaceutical patent law for almost twenty years. His practice includes representing clients in managing and strategizing complex patent prosecution, including interferences, reissues and reexaminations, patent infringement litigation, due diligence, licensing and counseling. Dr. Sonnenfeld's clients include both large multinational corporations, start up companies and non-profit foundations. Dr. Sonnenfeld received his M.A., M.Phil and Ph.D. in pharmacology from Columbia University and his J.D. from Fordham University Law School.

MaRS - Building Canada’s next generation of global technology companies. marsdd.com